SANA
NASDAQ · Biotechnology
Sana Biotechnology Inc
$3.51
+0.11 (+3.24%)
Open$3.44
Previous Close$3.40
Day High$3.54
Day Low$3.35
52W High$6.55
52W Low$2.61
Volume—
Avg Volume2.57M
Market Cap979.59M
P/E Ratio—
EPS$-0.94
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,041.9% upside
Current
$3.51
$3.51
Target
$40.08
$40.08
$23.55
$40.08 avg
$57.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 204.77M | 187.81M | 190.12M |
| Net Income | 17.06M | 14.80M | 14.99M |
| Profit Margin | 8.3% | 7.9% | 7.9% |
| EBITDA | 24.96M | 25.10M | 25.01M |
| Free Cash Flow | 20.72M | 16.56M | 17.82M |
| Rev Growth | +11.7% | +19.4% | -6.7% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |